AZ’s Lynparza inches towards ‘game changer’ okay in pancreat...

NICE backs Lynparza across the board for BRCA+ovarian cancer

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...

Strong results for AZ’s Lynparza will help in PARP battle

AstraZeneca has announced that its PARP inhibitor cancer treatment Lynparza has recorded strong results in a new phase 3 trial.<